About this Research Topic
We are pleased to introduce the Editor's Pick, Quarter 1, 2021. This collection showcases carefully selected articles published in the section over the previous quarter.
The work exhibited here spotlights the high-quality and diverse research carried out globally, and brings attention to recent areas of interest and advances within the field. The collection not only supports the work of the authors who have contributed their outstanding research to the journal, but also recognises the hard work of our Editorial Board of international researchers who contribute to the peer-review of such articles.
The Hematologic Malignancies section of Frontiers in Oncology is dedicated to clinical and basic research on all aspects of hematological malignancies, including acute and chronic leukemia, lymphoma and plasma and hematopoietic stem cell disorders.
We present here five publications published during the first quarter of 2021, carefully selected by the Specialty Chief Editor, Alessandro Isidori (AORMN, IT), and esteemed Associate Editors:
María-Victoria Mateos (University Hospital of Salamanca, ES), Cyrus Khandanpour (University Hospital Münster, DE), Stefano Luminari (University of Modena and Reggio Emilia, IT).
Frontiers in Oncology publishes rigorously peer-reviewed research advancing our knowledge of cancer epidemiology, molecular pathways, diagnosis and imaging, personalized therapeutics, and novel treatment and management strategies.
Keywords: hematologic malignancies, myeloma, leukemia, lymphoma, cancer biology
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.